CAR T-cell therapy: New Developments and Challenges

A Gentle Breakthrough: IIT Bombay’s Accutase Application in CAR T-Cell Therapy

On February 7, 2026, researchers at IIT Bombay unveiled a significant advancement in CAR T-cell therapy, addressing a critical bottleneck in the recovery of engineered T-cells from lab-grown scaffolds. By employing Accutase, a gentler enzyme, the team demonstrated improved cell viability and potency, a subtle yet impactful shift in immunotherapy that could redefine cost structures and accessibility in India. But breakthroughs carry as many questions as they do promises.

Breaking Tradition: Why This Research May Redefine Indian Cancer Care

This development breaks with India’s historic dependence on imported CAR T-cell technologies, such as those from U.S.-based firms like Novartis and Bristol Myers Squibb. In 2021, Novartis’ Kymriah—the first FDA-approved CAR-T therapy—came with a jaw-dropping price tag of over ₹3 crore per dose, making advanced immunotherapy an impossible dream for most Indian patients. In stark contrast, NexCAR19, the first humanised CAR-T therapy developed entirely in India by ImmunoACT, aims to bring costs to below ₹50 lakh per treatment.

What separates IIT Bombay's study is its focus on reducing production costs through innovations in cell culturing. The use of 3D fibrous scaffolds, which mimic the natural T-cell environment, holds enormous potential for scaling manufacturing. However, traditional methods for recovering these cells—manual flushing or harsher enzymes—compromise cell integrity or require expensive techniques, limiting efficacy. Enter Accutase, which solves this problem. Not only did recovered T-cells maintain viability, but their targeted killing of cancer cells remained reliably potent, promising greater clinical scalability while preserving functional precision.

The Machinery Behind Accutase and CAR T-Cell Therapy

The science underpinning CAR T-cell therapy reflects a complex interplay of genetic engineering, immunology, and biomanufacturing regulations. The therapy modifies T-cells to express chimeric antigen receptors (CARs) that act as homing beacons to recognise and attack cancer cells. Despite its revolutionary promise, indigenous efforts like NexCAR19 are rare due to its demanding prerequisites:

• Highly specialised facilities like Good Manufacturing Practice (GMP)-grade labs.
• Adherence to stringent monitoring under the Drugs and Cosmetics Act, 1940, which regulates biopharmaceutical products.
• Early-stage advancements in gene-editing tools, such as CRISPR, which ensure precision engineering.

IIT Bombay's scaffold innovation aligns with regulatory priorities by simplifying recovery—a step that often escalates the therapy's costs. Yet, these experiments remain laboratory-bound; translating this into a reproducible, scalable framework will depend on central funding, substantial public-private partnerships, and integration into the ecosystem of the National Biopharma Mission.

Ground Reality: What the Numbers Say About Accessibility

The government has expressed optimism about CAR T-cell therapy transforming cancer care, yet the actual metrics are far less glowing. The pilot project under Biotechnology Industry Research Assistance Council (BIRAC), funding NexCAR19's development, allocated just ₹56 crore. For a therapy where per-patient costs still hover around ₹50 lakh, this seed fund reflects inadequate scaling potential.

More troubling are the availability gaps. As of January 2026, India has fewer than 10 operational CAR-T therapy facilities, concentrated in metro cities like Mumbai, Delhi, and Bengaluru. This mirrors broader issues in specialised medical access: the rural-urban divide, consensus on pricing protocols under hospital accreditation structures, and inadequate training pipelines for immunotherapy specialists across state-run health institutions.

Despite promising pilot outcomes, efficacy remains uneven. Studies reported instances of tumor antigen escape, a phenomenon where cancer cells mutate or lose their target antigens, undermining therapy precision. Combined with risks of Cytokine Release Syndrome (CRS), CAR T-cell therapy's clinical safety remains contested, demanding stricter post-treatment surveillance.

Uncomfortable Questions: Are We Ready for the Next Step?

A persistent blind spot in the CAR T-cell narrative? India's weak automation infrastructure for biopharmaceutical production. Globally, firms like Cell Gene in Switzerland rely on AI-driven platforms to streamline lab-to-patient timelines and reduce manual intervention costs. Indian efforts, however, remain labour-intensive, diluting affordability benefits.

Another concern lies in regional equity. Take Tamil Nadu's cancer infrastructure versus Bihar's: the yawning disparity in oncology facilities suggests that NexCAR19 or similar therapies will remain exclusive. Without decentralised adoption models or direct subsidies under Ayushman Bharat, CAR T-cell therapy may just widen India's healthcare inequality.

The timeline for implementation also feels optimistic. While IIT Bombay’s scaffold development is geared towards animal trials and direct implantation methods, clinical trials require multi-phase rigour. Are Indian regulators like CDSCO equipped to fast-track trials while ensuring patient safety? It is unclear.

International Comparison: Lessons from South Korea

South Korea offers a striking point of contrast. In 2018, after facing prohibitive costs for CAR T-cell imports, the government subsidised domestic innovation under its K-BioHealth strategy. By leveraging public R&D institutions and incentivising generics manufacturers, Korea slashed therapy costs by over 40% in four years. India’s BIRAC, despite its efforts, lacks that scale. Replicating Korea’s success may require the central government to align high-budget healthcare missions (like Ayushman Bharat) directly with biopharma subsidies instead of treating them as siloed efforts.

Exam Integration

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions